Adult Dosing
Edema
- Usual dose: 50 - 200 mg PO daily
- Titration: The dose schedule may be helpful in determining the smallest effective dose
- Day 1 - 50 mg PO daily after a meal
- Day 2 - 50 mg PO twice daily after meals, if necessary
- Day 3 - 100 mg PO qam and 50 to 100 mg PO following the afternoon or evening meal, depending upon response to the morning dose
Short-term management of ascites (malignancy, idiopathic edema or lymphedema)
- Usual dose: 50 - 200 mg PO daily
- Titration: The dose schedule may be helpful in determining the smallest effective dose as follows
- Day 1 - 50 mg once daily after a meal
- Day 2 - 50 mg twice daily after meals, if necessary
- Day 3 - 100 mg in the morning and 50 to 100 mg following the afternoon or evening meal, depending upon response to the morning dose
Note: Dose and dose schedule must be adjusted to the individual patient's needs to prevent a more rapid or substantial loss of fluid or electrolyte than is indicated or necessary
Pediatric Dosing
Edema
Child >2 yrs
- Usual dose: 25 mg PO daily
- Titration: increase 25 mg/day PO q2-3 days to desired therapeutic response
- Max: 3 mg/kg/day
- ALT: 1 mg/kg PO daily for hospitalized patients with congenital heart disease or nephrotic syndrome
Short-term management of ascites (malignancy, idiopathic edema or lymphedema)
Child >2 yrs
- Usual dose: 25 mg PO daily
- Titration: Increase 25 mg/day PO q2-3 days
- Max: 3 mg/kg/day
- ALT: 1 mg/kg PO daily for hospitalized patients with congenital heart disease or nephrotic syndrome
Note: Dose and dose schedule must be adjusted to the individual patient's needs to prevent a more rapid or substantial loss of fluid or electrolyte than is indicated or necessary
[Outline]
- Avoid profound electrolyte and water loss by weighing the patient throughout the treatment period. Reduce dosage or suspend therapy when excessive electrolyte loss occurs
- Administer cautiously in patients with a history of previous episodes of electrolyte imbalance or hepatic encephalopathy to avoid precipitation of hepatic coma and death
- Deaths have been reported in patients with severe myocardial disease who have been receiving digitalis and in patients with severely decompensated hepatic cirrhosis with ascites
- Do not administer lithium with diuretics
- Therapy may cause weakness, muscle cramps, paresthesias, thirst, anorexia, and signs of hyponatremia, hypokalemia, and/or hypochloremic alkalosis following vigorous or excessive diuresis
- In patients receiving other antihypertensive agents orthostatic hypotension may occur
- Monitor fluid status and renal function
- Hypomagnesemia may occur due to increased urinary excretion of magnesium
- Suspend therapy if a transient increase in serum urea nitrogen
- Increased risk of gastric hemorrhage associated with corticosteroid treatment has been reported with the therapy
Cautions: Use cautiously in
- Hepatic impairment
- Advanced cirrhosis of the liver
- History of previous episodes of electrolyte imbalance
- History of hepatic encephalopathy
- Diabetes mellitus
- Increasing azotemia
- Elderly cardiac patients
Pregnancy Category:B
Breastfeeding: Safety unknown, use with caution; an alternate drug may be preferred, especially while nursing a newborn or preterm infant based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 February 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer advises discontinuation of nursing or discontinuation of the drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Edecrin 25 MG TABS [Bottle] (VALEANT)
100 mg = $375.24
300 mg = $1056.81
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Edecrin 25 MG Oral Tablet
Ingredient(s): Ethacrynate
Imprint: ATON;205;EDECRIN
Color(s): White
Shape: Oval
Size (mm): 10.00
Score: 2
Inactive Ingredient(s): silicon dioxide / lactose / magnesium stearate / talc
Drug Label Author:
Aton Pharma, Inc.
DEA Schedule:
Non-Scheduled
Drug Name: Edecrin 25 MG Oral Tablet
Pill Image:
[
See full size image]
Ingredient(s): Ethacrynate
Imprint: MSD;65;EDECRIN
Color(s): White
Shape: Oval
Size (mm): 10.00
Score: 2
Inactive Ingredient(s): colloidal silicon dioxide / lactose / magnesium stearate / starch / talc
Drug Label Author:
MERCK and CO.
DEA Schedule:
Non-Scheduled
